amphotericin B lipid complex

Amphotericin B lipid complex is a broad-spectrum antifungal drug used to treat serious, life-threatening fungal infections in patients who are unresponsive to or unable to tolerate conventional amphotericin B therapy[1][2][4]. It consists of amphotericin B complexed with two phospholipids—L-α-dimyristoylphosphatidylcholine (DMPC) and L-α-dimyristoylphosphatidylglycerol (DMPG)—in a 7:3 molar ratio, forming ribbon-like structures[5][6]. The lipid formulation alters the pharmacokinetics and tissue distribution of the drug, resulting in reduced nephrotoxicity compared to conventional formulations. Amphotericin B exerts its antifungal effect by binding to ergosterol in fungal cell membranes, creating pores that lead to cell death. The primary indication is for invasive fungal infections refractory or intolerant to standard therapy[1][3][4]. Developed by: Liposome Company Manufactured by: Pfizer

Brand names

Abelcet

Other names

amphotericin B lipid complexABLC